Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Adenocarcinoma
Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Adenocarcinoma
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
Adenocarcinoma
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Adenocarcinoma
Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
Adenocarcinoma
Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A.
Adenocarcinoma
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Adenocarcinoma
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Adenocarcinoma
The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma.
Adenocarcinoma of Lung
Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.
Adenocarcinoma of Lung
Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma.
Adenocarcinoma, Bronchiolo-Alveolar
Expression of dual-specificity tyrosine-(Y)-phosphorylation-regulated kinase 2 (DYRK2) can be a favorable prognostic marker in pulmonary adenocarcinoma.
Albinism
Ocular findings of albinism in DYRK1A-related intellectual disability syndrome.
Alzheimer Disease
?-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
Alzheimer Disease
A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
Alzheimer Disease
A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase.
Alzheimer Disease
A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Alzheimer Disease
Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
Alzheimer Disease
Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice.
Alzheimer Disease
Chemical screening identifies the ?-Carboline alkaloid harmine to be synergistically lethal with doxorubicin.
Alzheimer Disease
Combined assessment of DYRK1A, BDNF and homocysteine levels as diagnostic marker for Alzheimer's disease.
Alzheimer Disease
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Alzheimer Disease
Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
Alzheimer Disease
Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
Alzheimer Disease
Development of novel 2,4-bispyridyl thiophene-based compounds as highly potent and selective Dyrk1A inhibitors. Part I: Benzamide and benzylamide derivatives.
Alzheimer Disease
Development of novel amide-derivatized 2,4-bispyridyl thiophenes as highly potent and selective Dyrk1A inhibitors. Part II: Identification of the cyclopropylamide moiety as a key modification.
Alzheimer Disease
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
Alzheimer Disease
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1a (DYRK1a) Kinase Inhibitors as Potential Therapeutics.
Alzheimer Disease
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Alzheimer Disease
Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.
Alzheimer Disease
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Alzheimer Disease
DYRK1A genetic variants are not linked to Alzheimer's disease in a Spanish case-control cohort.
Alzheimer Disease
Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass.
Alzheimer Disease
DYRK1A inhibition as potential treatment for Alzheimer's disease.
Alzheimer Disease
DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
Alzheimer Disease
Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
Alzheimer Disease
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.
Alzheimer Disease
E3 Ligase SCF?TrCP-induced DYRK1A Protein Degradation Is Essential for Cell Cycle Progression in HEK293 Cells.
Alzheimer Disease
Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors.
Alzheimer Disease
GSK-3?, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways.
Alzheimer Disease
Hologram QSAR Models of a Series of 6-Arylquinazolin-4-Amine Inhibitors of a New Alzheimer's Disease Target: Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase-1A Enzyme.
Alzheimer Disease
Identification of a DYRK1A Inhibitor that Induces Degradation of the Target Kinase using Co-chaperone CDC37 fused with Luciferase nanoKAZ.
Alzheimer Disease
Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.
Alzheimer Disease
Inhibition of DYRK1A proteolysis modifies its kinase specificity and rescues Alzheimer phenotype in APP/PS1 mice.
Alzheimer Disease
Kororamides, Convolutamines, and Indole Derivatives as Possible Tau and Dual-Specificity Kinase Inhibitors for Alzheimer's Disease: A Computational Study.
Alzheimer Disease
LPS-Induced Inflammation Abolishes the Effect of DYRK1A on IkB Stability in the Brain of Mice.
Alzheimer Disease
Meridianins: marine-derived potent kinase inhibitors.
Alzheimer Disease
microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing.
Alzheimer Disease
Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
Alzheimer Disease
Overexpression of miR-26a-5p suppresses Tau phosphorylation and A? accumulation in Alzheimer's disease mice by targeting DYRK1A.
Alzheimer Disease
Oxidative and nitrosative modifications of biliverdin reductase-a in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment.
Alzheimer Disease
Phosphorylation of Munc18-1 by Dyrk1A regulates its interaction with Syntaxin 1 and X11?.
Alzheimer Disease
Plasma DYRK1A as a novel risk factor for Alzheimer's disease.
Alzheimer Disease
Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Alzheimer Disease
Probing the ATP-Binding Pocket of Protein Kinase DYRK1A with Benzothiazole Fragment Molecules.
Alzheimer Disease
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Alzheimer Disease
Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
Alzheimer Disease
REST Regulates DYRK1A Transcription in a Negative Feedback Loop.
Alzheimer Disease
Restrained Phosphatidylcholine Synthesis in a Cellular Model of Down's Syndrome is Associated with the Overexpression of Dyrk1A.
Alzheimer Disease
Selectivity Profiling and Biological Activity of Novel ?-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
Alzheimer Disease
Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
Alzheimer Disease
Synthesis and kinase inhibitory activity of novel substituted indigoids.
Alzheimer Disease
Synthesis and preliminary in vitro kinase inhibition evaluation of new diversely substituted pyrido[3,4-g]quinazoline derivatives.
Alzheimer Disease
Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
Alzheimer Disease
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
Alzheimer Disease
The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
Alzheimer Disease
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
Alzheimer Disease
Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.
Alzheimer Disease
[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors.
Amblyopia
Ocular Phenotype Associated with DYRK1A Variants.
Anemia
Crystal Structure of Human Dual-Specificity Tyrosine-Regulated Kinase 3 Reveals New Structural Features and Insights into its Auto-phosphorylation.
Anemia
DYRK3 dual-specificity kinase attenuates erythropoiesis during anemia.
Anemia, Hemolytic
DYRK3 dual-specificity kinase attenuates erythropoiesis during anemia.
Arthritis, Rheumatoid
Dyrk1A promotes the proliferation, migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis via down-regulating Spry2 and activating the ERK MAPK pathway.
Bone Resorption
Negative-feedback inhibition of NFATc1 by DYRK1A regulates bone homeostasis.
Brain Neoplasms
DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.
Brain Neoplasms
Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Brain Neoplasms
Systematic diversification of benzylidene heterocycles yields novel inhibitor scaffolds selective for Dyrk1A, Clk1 and CK2.
Breast Neoplasms
A novel gene STYK1/NOK is upregulated in estrogen receptor-alpha negative estrogen receptor-beta positive breast cancer cells following estrogen treatment.
Breast Neoplasms
Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways.
Breast Neoplasms
Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Breast Neoplasms
Diminished DYRK2 sensitizes hormone receptor-positive breast cancer to everolimus by the escape from degrading mTOR.
Breast Neoplasms
Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Breast Neoplasms
Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.
Breast Neoplasms
Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Breast Neoplasms
Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
Breast Neoplasms
DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Breast Neoplasms
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Breast Neoplasms
Dyrk2-associated EDD-DDB1-VprBP E3 Ligase Inhibits Telomerase by TERT Degradation.
Breast Neoplasms
Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
Breast Neoplasms
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Breast Neoplasms
Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Carcinogenesis
Association of chromosome 19 to lung cancer genotypes and phenotypes.
Carcinogenesis
CIRBP Knockdown Attenuates Tumourigenesis and Improves the Chemosensitivity of Pancreatic Cancer via the Downregulation of DYRK1B.
Carcinogenesis
DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
Carcinogenesis
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
Carcinogenesis
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
Carcinogenesis
DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.
Carcinogenesis
Exome sequencing identifies early gastric carcinoma as an early stage of advanced gastric cancer.
Carcinogenesis
Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
Carcinogenesis
Impairment of DYRK2 by DNMT1?mediated transcription augments carcinogenesis in human colorectal cancer.
Carcinogenesis
Increased expression of Dyrk1a in HPV16 immortalized keratinocytes enable evasion of apoptosis.
Carcinogenesis
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression.
Carcinogenesis
MiR-1246: A new link of the p53 family with cancer and Down syndrome.
Carcinogenesis
Targeting dual specificity protein kinase TTK attenuates tumorigenesis of glioblastoma.
Carcinogenesis
The overexpression of RHAMM, a hyaluronan-binding protein that regulates ras signaling, correlates with overexpression of mitogen-activated protein kinase and is a significant parameter in breast cancer progression.
Carcinogenesis
[Proteomic analysis of proteins related to radiation-induced carcinogenesis]
Carcinoma
A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Carcinoma
Corrigendum: A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Carcinoma
DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma.
Carcinoma
Effects of marine sponge extracts on mitogen-activated protein kinase (MAPK/ERK(1,2)) activity in SW-13 human adrenal carcinoma cells.
Carcinoma
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Carcinoma
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
Carcinoma
STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma.
Carcinoma, Ehrlich Tumor
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Carcinoma, Embryonal
Isolation and characterization of activin receptor from mouse embryonal carcinoma cells. Identification of its serine/threonine/tyrosine protein kinase activity.
Carcinoma, Embryonal
Multiple cDNAs encoding the esk kinase predict transmembrane and intracellular enzyme isoforms.
Carcinoma, Hepatocellular
Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma.
Carcinoma, Hepatocellular
Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 3 Loss Activates Purine Metabolism and Promotes Hepatocellular Carcinoma Progression.
Carcinoma, Hepatocellular
DYRK1 is a co-activator of FKHR (FOXO1a)-dependent glucose-6-phosphatase gene expression.
Carcinoma, Hepatocellular
TROAP switches DYRK1 activity to drive hepatocellular carcinoma progression.
Carcinoma, Non-Small-Cell Lung
DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer.
Carcinoma, Non-Small-Cell Lung
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Carcinoma, Non-Small-Cell Lung
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Carcinoma, Non-Small-Cell Lung
STYK1/NOK correlates with ferroptosis in non-small cell lung carcinoma.
Carcinoma, Non-Small-Cell Lung
STYK1/NOK Promotes Metastasis and Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer by Suppressing FoxO1 Signaling.
Carcinoma, Squamous Cell
A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
Corrigendum: A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Carcinoma, Squamous Cell
DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma.
Cardiomegaly
Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling.
Cardiomegaly
Enhanced expression of DYRK1A in cardiomyocytes inhibits acute NFAT activation but does not prevent hypertrophy in vivo.
Cardiomegaly
Hyperhomocysteinemia-induced Dyrk1a downregulation results in cardiomyocyte hypertrophy in rats.
Cardiomegaly
MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling.
Cardiomyopathies
Dyrk1a regulates the cardiomyocyte cell cycle via D-cyclin-dependent Rb/E2f-signalling.
Cardiotoxicity
Chemical screening identifies the ?-Carboline alkaloid harmine to be synergistically lethal with doxorubicin.
Coffin-Lowry Syndrome
High diagnostic yield of clinically unidentifiable syndromic growth disorders by targeted exome sequencing.
Colorectal Neoplasms
Decrease of miR-622 expression suppresses migration and invasion by targeting regulation of DYRK2 in colorectal cancer cells.
Colorectal Neoplasms
Diagnostic relevance of overexpressed serine threonine tyrosine kinase/novel oncogene with kinase domain (STYK1/ NOK) mRNA in colorectal cancer.
Colorectal Neoplasms
Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Colorectal Neoplasms
Impairment of DYRK2 by DNMT1?mediated transcription augments carcinogenesis in human colorectal cancer.
Colorectal Neoplasms
LncRNA OIP5-AS1 regulates radioresistance by targeting DYRK1A through miR-369-3p in colorectal cancer cells.
Colorectal Neoplasms
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Congenital Abnormalities
DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
Corneal Opacity
Microdeletion of the Down syndrome critical region at 21q22.
Craniofacial Abnormalities
Influence of Prenatal EGCG Treatment and Dyrk1a Dosage Reduction on Craniofacial Features Associated with Down Syndrome.
Craniofacial Abnormalities
Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
cyclin-dependent kinase deficiency
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
cyclin-dependent kinase deficiency
The green tea polyphenol epigallocatechin-3-gallate (EGCG) restores CDKL5-dependent synaptic defects in vitro and in vivo.
Dementia
A Pilot Study Examining Associations between DYRK1A and ?-Synuclein Dementias.
Dementia
Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
Dementia
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Dementia
microRNA 155 up regulation in the CNS is strongly correlated to Down's syndrome dementia.
Dementia
The role of DYRK1A in neurodegenerative diseases.
Dengue
Host factor prioritization for pan-viral genetic perturbation screens using random intercept models and network propagation.
Diabetes Mellitus
DYRK1A aggravates ? cell dysfunction and apoptosis by promoting the phosphorylation and degradation of IRS2.
Diabetes Mellitus, Type 1
Selective DYRK1A Inhibitor for the Treatment of Type 1 Diabetes: Discovery of 6-Azaindole Derivative GNF2133.
Diabetes Mellitus, Type 2
Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human ?-Cell Proliferation.
Diabetes Mellitus, Type 2
Two novel variants in DYRK1B causative of AOMS3: expanding the clinical spectrum.
Down Syndrome
10-Iodo-11H-indolo[3,2-c]quinoline-6-carboxylic Acids Are Selective Inhibitors of DYRK1A.
Down Syndrome
?-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
Down Syndrome
A chemical with proven clinical safety rescues Down-syndrome-related phenotypes in through DYRK1A inhibition.
Down Syndrome
A commentary on: Overexpression of Dyrk1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
Down Syndrome
A comprehensive proteomics-based interaction screen that links DYRK1A to RNF169 and to the DNA damage response.
Down Syndrome
A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase.
Down Syndrome
A novel DYRK1A (Dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Down Syndrome
A patient with Down syndrome with a de novo derivative chromosome 21.
Down Syndrome
A repressor complex, AP4 transcription factor and geminin, negatively regulates expression of target genes in nonneuronal cells.
Down Syndrome
Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
Down Syndrome
Activation, regulation, and inhibition of DYRK1A.
Down Syndrome
Activity-Dependent Phosphorylation of Dynamin 1 at Serine 857.
Down Syndrome
Age-associated motor and visuo-spatial learning phenotype in Dyrk1A heterozygous mutant mice.
Down Syndrome
Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse.
Down Syndrome
Aristolactam BIII, a naturally derived DYRK1A inhibitor, rescues Down syndrome-related phenotypes.
Down Syndrome
Association of the single nucletide polymorphisms in RUNX1, DYRK1A, and KCNJ15 with blood related traits in pigs.
Down Syndrome
Attenuation of Notch signalling by the Down-syndrome-associated kinase DYRK1A.
Down Syndrome
BDNF and DYRK1A Are Variable and Inversely Correlated in Lymphoblastoid Cell Lines from Down Syndrome Patients.
Down Syndrome
Bioinformatics analysis of biomarkers and transcriptional factor motifs in Down syndrome.
Down Syndrome
Cannabinoid type-1 receptor blockade restores neurological phenotypes in two models for Down syndrome.
Down Syndrome
Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a.
Down Syndrome
Cerebellar alterations in a model of Down syndrome: The role of the Dyrk1A gene.
Down Syndrome
Characterization of Caenorhabditis elegans homologs of the Down syndrome candidate gene DYRK1A.
Down Syndrome
Characterization of the human DYRK1A promoter and its regulation by the transcription factor E2F1.
Down Syndrome
Clinical manifestations of the deletion of Down syndrome critical region including DYRK1A and KCNJ6.
Down Syndrome
Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases.
Down Syndrome
Cloning of a human homolog of the Drosophila minibrain/rat Dyrk gene from "the Down syndrome critical region" of chromosome 21.
Down Syndrome
Comparative analysis of the DYRK1A-SRSF6-TNNT2 pathway in myocardial tissue from individuals with and without Down syndrome.
Down Syndrome
Computational & experimental evaluation of the structure/activity relationship of ?-carbolines as DYRK1A inhibitors.
Down Syndrome
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Down Syndrome
Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
Down Syndrome
Cyclin D1 Again Caught in the Act: Dyrk1a Links G1 and Neurogenesis in Down Syndrome.
Down Syndrome
DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B.
Down Syndrome
Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A.
Down Syndrome
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
Down Syndrome
Disruption of neurogenesis and cortical development in transgenic mice misexpressing Olig2, a gene in the Down syndrome critical region.
Down Syndrome
Down syndrome and thyroid dysfunction: should nutritional support be the first-line treatment?
Down Syndrome
Down syndrome phenotype in a boy with a mosaic microduplication of chromosome 21q22.
Down Syndrome
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.
Down Syndrome
Down's syndrome-like cardiac developmental defects in embryos of the transchromosomic Tc1 mouse.
Down Syndrome
Down's-syndrome-related kinase Dyrk1A modulates the p120-catenin-Kaiso trajectory of the Wnt signaling pathway.
Down Syndrome
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1a (DYRK1a) Kinase Inhibitors as Potential Therapeutics.
Down Syndrome
Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Enhances Tau Expression.
Down Syndrome
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Down Syndrome
Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Modulates Serine/Arginine-rich Protein 55 (SRp55)-promoted Tau Exon 10 Inclusion.
Down Syndrome
Dual-specificity tyrosine phosphorylation-regulated kinase 1A does not require tyrosine phosphorylation for activity in vitro.
Down Syndrome
Dual-specificity tyrosine-phosphorylated and regulated kinase 1A (DYRK1A) interacts with the phytanoyl-CoA alpha-hydroxylase associated protein 1 (PAHX-AP1), a brain specific protein.
Down Syndrome
Dual-specificity tyrosine-phosphorylation regulated kinase 1A Gene Transcription is regulated by Myocyte Enhancer Factor 2D.
Down Syndrome
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Down Syndrome
DYRK1A (dual-specificity tyrosine-phosphorylated and -regulated kinase 1A): a gene with dosage effect during development and neurogenesis.
Down Syndrome
DYRK1A and cognition: A lifelong relationship.
Down Syndrome
DYRK1A and DYRK3 promote cell survival through phosphorylation and activation of SIRT1.
Down Syndrome
DYRK1A BAC Transgenic Mouse: A New Model of Thyroid Dysgenesis in Down Syndrome.
Down Syndrome
DYRK1A binds to an evolutionarily conserved WD40-repeat protein WDR68 and induces its nuclear translocation.
Down Syndrome
DYRK1A enhances the mitogen-activated protein kinase cascade in PC12 cells by forming a complex with Ras, B-Raf, and MEK1.
Down Syndrome
Dyrk1A haploinsufficiency affects viability and causes developmental delay and abnormal brain morphology in mice.
Down Syndrome
Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass.
Down Syndrome
DYRK1A in Down syndrome: an oncogene or tumor suppressor?
Down Syndrome
Dyrk1A induces pancreatic ? cell mass expansion and improves glucose tolerance.
Down Syndrome
DYRK1A inhibition and cognitive rescue in a Down syndrome mouse model are induced by new fluoro-DANDY derivatives.
Down Syndrome
DYRK1A interacts with the REST/NRSF-SWI/SNF chromatin remodelling complex to deregulate gene clusters involved in the neuronal phenotypic traits of Down syndrome.
Down Syndrome
Dyrk1A is dynamically expressed on subsets of motor neurons and in the neuromuscular junction: possible role in Down syndrome.
Down Syndrome
DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective.
Down Syndrome
DYRK1A overexpression decreases plasma lecithin:cholesterol acyltransferase activity and apolipoprotein A-I levels.
Down Syndrome
DYRK1A overexpression enhances STAT activity and astrogliogenesis in a Down syndrome mouse model.
Down Syndrome
Dyrk1A overexpression in immortalized hippocampal cells produces the neuropathological features of Down syndrome.
Down Syndrome
Dyrk1A overexpression inhibits proliferation and induces premature neuronal differentiation of neural progenitor cells.
Down Syndrome
Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
Down Syndrome
DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine.
Down Syndrome
Dyrk1A potentiates steroid hormone-induced transcription via the chromatin remodeling factor Arip4.
Down Syndrome
DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease.
Down Syndrome
DYRK1A Protein, A Promising Therapeutic Target to Improve Cognitive Deficits in Down Syndrome.
Down Syndrome
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.
Down Syndrome
DYRK1A regulates Hap1-Dcaf7/WDR68 binding with implication for delayed growth in Down syndrome.
Down Syndrome
DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.
Down Syndrome
DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase.
Down Syndrome
DYRK1A-mediated Cyclin D1 Degradation in Neural Stem Cells Contributes to the Neurogenic Cortical Defects in Down Syndrome.
Down Syndrome
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
Down Syndrome
DYRK1A: a potential drug target for multiple Down syndrome neuropathologies.
Down Syndrome
DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.
Down Syndrome
E3 Ligase SCF?TrCP-induced DYRK1A Protein Degradation Is Essential for Cell Cycle Progression in HEK293 Cells.
Down Syndrome
Epigallocatechin-3-gallate (EGCG) consumption in the Ts65Dn model of Down syndrome fails to improve behavioral deficits and is detrimental to skeletal phenotypes.
Down Syndrome
Epigallocatechin-3-Gallate Plus Omega-3 Restores the Mitochondrial Complex I and F0F1-ATP Synthase Activities in PBMCs of Young Children with Down Syndrome: A Pilot Study of Safety and Efficacy.
Down Syndrome
Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans.
Down Syndrome
Evaluation of the therapeutic potential of Epigallocatechin-3-gallate (EGCG) via oral gavage in young adult Down syndrome mice.
Down Syndrome
Expression of the DYRK1A gene correlates with its 3D positioning in the interphase nucleus of Down syndrome cells.
Down Syndrome
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
Down Syndrome
Function and regulation of Dyrk1A: towards understanding Down syndrome.
Down Syndrome
Gene dosage-dependent association of DYRK1A with the cytoskeleton in the brain and lymphocytes of down syndrome patients.
Down Syndrome
Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
Down Syndrome
Global kinome profiling reveals DYRK1A as critical activator of the human mitochondrial import machinery.
Down Syndrome
Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
Down Syndrome
Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation.
Down Syndrome
Identification of a novel actin-dependent signal transducing module allows for the targeted degradation of GLI1.
Down Syndrome
Impaired development of neocortical circuits contributes to the neurological alterations in DYRK1A haploinsufficiency syndrome.
Down Syndrome
Importance of gene dosage in controlling dendritic arbor formation during development.
Down Syndrome
Increased Dosage of Dyrk1A Alters Alternative Splicing Factor (ASF)-regulated Alternative Splicing of Tau in Down Syndrome.
Down Syndrome
Increased dosage of DYRK1A and brain volumetric alterations in a YAC model of partial trisomy 21.
Down Syndrome
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Down Syndrome
Increased NR2A expression and prolonged decay of NMDA-induced calcium transient in cerebellum of TgDyrk1A mice, a mouse model of Down syndrome.
Down Syndrome
Indole-3-Carbonitriles as DYRK1A Inhibitors by Fragment-Based Drug Design.
Down Syndrome
Influence of Prenatal EGCG Treatment and Dyrk1a Dosage Reduction on Craniofacial Features Associated with Down Syndrome.
Down Syndrome
Influence of prenatal EGCG treatment and Dyrk1a dosage reduction on craniofacial features associated with Down syndrome.
Down Syndrome
Inhibition of DYRK1A disrupts neural lineage specification in human pluripotent stem cells.
Down Syndrome
Intellectual disabilities, neuronal posttranscriptional RNA metabolism, and RNA-binding proteins: three actors for a complex scenario.
Down Syndrome
Intracellular distribution of differentially phosphorylated dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A).
Down Syndrome
Link between DYRK1A overexpression and several-fold enhancement of neurofibrillary degeneration with 3-repeat tau protein in Down syndrome.
Down Syndrome
Long-term running alleviates some behavioral and molecular abnormalities in Down syndrome mouse model Ts65Dn.
Down Syndrome
LPS-Induced Inflammation Abolishes the Effect of DYRK1A on IkB Stability in the Brain of Mice.
Down Syndrome
Mice Deficient in Cystathionine Beta Synthase Display Increased Dyrk1A and SAHH Activities in Brain.
Down Syndrome
Microdeletion of the Down syndrome critical region at 21q22.
Down Syndrome
microRNAs expression correlates with levels of APP, DYRK1A, hyperphosphorylated Tau and BDNF in the hippocampus of a mouse model for Down syndrome during ageing.
Down Syndrome
Minibrain drives the Dacapo-dependent cell cycle exit of neurons in the Drosophila brain by promoting asense and prospero expression.
Down Syndrome
MiR-1246: A new link of the p53 family with cancer and Down syndrome.
Down Syndrome
Molecular Rescue of Dyrk1A Overexpression Alterations in Mice with Fontup® Dietary Supplement: Role of Green Tea Catechins.
Down Syndrome
Motor phenotypic alterations in TgDyrk1a transgenic mice implicate DYRK1A in Down syndrome motor dysfunction.
Down Syndrome
Negative-feedback inhibition of NFATc1 by DYRK1A regulates bone homeostasis.
Down Syndrome
Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
Down Syndrome
New Perspectives of Dyrk1A Role in Neurogenesis and Neuropathologic Features of Down Syndrome.
Down Syndrome
NFAT dysregulation by increased dosage of DSCR1 and DYRK1A on chromosome 21.
Down Syndrome
Normalization of Dyrk1A expression by AAV2/1-shDyrk1A attenuates hippocampal-dependent defects in the Ts65Dn mouse model of Down syndrome.
Down Syndrome
Normalizing the gene dosage of Dyrk1A in a mouse model of Down syndrome rescues several Alzheimer's disease phenotypes.
Down Syndrome
Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors.
Down Syndrome
Nuclear import of the DSCAM-cytoplasmic domain drives signaling capable of inhibiting synapse formation.
Down Syndrome
Ocular Phenotype Associated with DYRK1A Variants.
Down Syndrome
Optimization and validation of a DYRK1A TR-FRET assay for high-throughput screening.
Down Syndrome
Overexpression of Dyrk1A Causes the Defects in Synaptic Vesicle Endocytosis.
Down Syndrome
Overexpression of Dyrk1A contributes to neurofibrillary degeneration in Down syndrome.
Down Syndrome
Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
Down Syndrome
Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
Down Syndrome
Overexpression of DYRK1A, a Down Syndrome Candidate gene, Impairs Primordial Germ Cells Maintenance and Migration in zebrafish.
Down Syndrome
Overexpression of Dyrk1A, a Down Syndrome Candidate, Decreases Excitability and Impairs Gamma Oscillations in the Prefrontal Cortex.
Down Syndrome
Phosphorylation of Munc18-1 by Dyrk1A regulates its interaction with Syntaxin 1 and X11?.
Down Syndrome
Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling.
Down Syndrome
Prefrontal deficits in a murine model overexpressing the down syndrome candidate gene dyrk1a.
Down Syndrome
Protein quality control of DYRK family protein kinases by the Hsp90-Cdc37 molecular chaperone.
Down Syndrome
QSAR and Pharmacophore Study of Dyrk1A Inhibitory Meridianin Analogs as Potential Agents for Treatment of Neurodegenerative Diseases.
Down Syndrome
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Down Syndrome
Regulation of RCAN1 protein activity by Dyrk1A protein-mediated phosphorylation.
Down Syndrome
Regulation of the alternative splicing of tau exon 10 by SC35 and Dyrk1A.
Down Syndrome
Regulation of the proapoptotic activity of huntingtin interacting protein 1 by Dyrk1 and caspase-3 in hippocampal neuroprogenitor cells.
Down Syndrome
Rescue of the abnormal skeletal phenotype in Ts65Dn Down syndrome mice using genetic and therapeutic modulation of trisomic Dyrk1a.
Down Syndrome
REST Regulates DYRK1A Transcription in a Negative Feedback Loop.
Down Syndrome
Restoring microglial and astroglial homeostasis using DNA immunization in a Down Syndrome mouse model.
Down Syndrome
Restrained Phosphatidylcholine Synthesis in a Cellular Model of Down's Syndrome is Associated with the Overexpression of Dyrk1A.
Down Syndrome
Selective DYRK1A Inhibitor for the Treatment of Neurodegenerative Diseases: Alzheimer, Parkinson, Huntington, and Down Syndrome.
Down Syndrome
Selectivity Profiling and Biological Activity of Novel ?-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
Down Syndrome
Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
Down Syndrome
Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity.
Down Syndrome
Targeting Dyrk1A with AAVshRNA Attenuates Motor Alterations in TgDyrk1A, a Mouse Model of Down Syndrome.
Down Syndrome
Targeting trisomic treatments: optimizing Dyrk1a inhibition to improve Down syndrome deficits.
Down Syndrome
Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.
Down Syndrome
The direct association of Sprouty-related protein with an EVH1 domain (SPRED) 1 or SPRED2 with DYRK1A modifies substrate/kinase interactions.
Down Syndrome
The Down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4.
Down Syndrome
The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation.
Down Syndrome
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy.
Down Syndrome
The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
Down Syndrome
The MNB/DYRK1A protein kinase: genetic and biochemical properties.
Down Syndrome
The neurodevelopmental disorder risk gene DYRK1A is required for ciliogenesis and control of brain size in Xenopus embryos.
Down Syndrome
The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair.
Down Syndrome
The protein kinase DYRK1A regulates caspase-9-mediated apoptosis during retina development.
Down Syndrome
The role of DYRK1A in neurodegenerative diseases.
Down Syndrome
The role of overexpressed DYRK1A protein in the early onset of neurofibrillary degeneration in Down syndrome.
Down Syndrome
Therapeutic Effects of Catechins in Less Common Neurological and Neurodegenerative Disorders.
Down Syndrome
Transgenic mouse in vivo library of human Down syndrome critical region 1: association between DYRK1A overexpression, brain development abnormalities, and cell cycle protein alteration.
Down Syndrome
Transient myeloproliferative disorder with partial trisomy 21.
Down Syndrome
Translating dosage compensation to trisomy 21.
Down Syndrome
Triple play of DYRK1A kinase in cortical progenitor cells of Trisomy 21.
Down Syndrome
Triplication of DYRK1A causes retinal structural and functional alterations in Down syndrome.
Down Syndrome
Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.
Down Syndrome
Truncation and Activation of Dual Specificity Tyrosine Phosphorylation-regulated Kinase 1A by Calpain I: A MOLECULAR MECHANISM LINKED TO TAU PATHOLOGY IN ALZHEIMER DISEASE.
Down Syndrome
Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly.
Down Syndrome
Two key genes closely implicated with the neuropathological characteristics in Down syndrome: DYRK1A and RCAN1.
Down Syndrome
Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.
Down Syndrome
Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish.
Down Syndrome
[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors.
Down Syndrome
[Minibrain/DYRK1A gene: candidate gene for mental retardation in Down's syndrome?]
Down Syndrome
[Trisomy 21: fifty years between medicine and science]
dual-specificity kinase deficiency
Arabidopsis YAK1 regulates abscisic acid response and drought resistance.
dual-specificity kinase deficiency
DYRK1A and cognition: A lifelong relationship.
dual-specificity kinase deficiency
DYRK1A Is a Regulator of S-Phase Entry in Hepatic Progenitor Cells.
dual-specificity kinase deficiency
DYRK1a mediates BAFF-induced noncanonical NF-kB activation to promote autoimmunity and B cell leukemogenesis.
dual-specificity kinase deficiency
DYRK3 dual-specificity kinase attenuates erythropoiesis during anemia.
Epilepsy
Clinical course of epilepsy and white matter abnormality linked to a novel DYRK1A variant.
Epilepsy
Clinical manifestations of the deletion of Down syndrome critical region including DYRK1A and KCNJ6.
Epilepsy
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy.
Fetal Growth Retardation
Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly.
Frontotemporal Lobar Degeneration
GSK-3?, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways.
Glioblastoma
An ID2-dependent mechanism for VHL inactivation in cancer.
Glioblastoma
Dual Specificity Kinase DYRK3 Promotes Aggressiveness of Glioblastoma by Altering Mitochondrial Morphology and Function.
Glioblastoma
DYRK1A activates NFATC1 to increase glioblastoma migration.
Glioblastoma
DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.
Glioblastoma
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells.
Glioblastoma
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Glioblastoma
Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence.
Glioblastoma
Multiple forms of protein kinase from normal human brain and glioblastoma.
Glioblastoma
NOK mediated mitogenic signaling is altered by P203L and V395I mutations.
Glioblastoma
Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
Glioblastoma
Targeting dual specificity protein kinase TTK attenuates tumorigenesis of glioblastoma.
Glioma
An ID2-dependent mechanism for VHL inactivation in cancer.
Glioma
DYRK1A activates NFATC1 to increase glioblastoma migration.
Glioma
Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Glioma
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Glioma
K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR.
Glioma
Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation.
Glioma
Protein kinase translocation following beta-adrenergic receptor activation in C6 glioma cells.
Glioma
Regulation of Glioma Cells Migration by DYRK2.
Hearing Loss, Sensorineural
Novel Causative Variants in DYRK1A, KARS, and KAT6A Associated with Intellectual Disability and Additional Phenotypic Features.
Heart Failure
Involvement of the dual-specificity tyrosine phosphorylation-regulated kinase 1A-alternative splicing factor-calcium/calmodulin-dependent protein kinase II? signaling pathway in myocardial infarction-induced heart failure of rats.
Heart Failure
MicroRNA-199b targets the nuclear kinase Dyrk1a in an auto-amplification loop promoting calcineurin/NFAT signalling.
Hepatitis
High diagnostic yield of clinically unidentifiable syndromic growth disorders by targeted exome sequencing.
Hepatitis C
Host factor prioritization for pan-viral genetic perturbation screens using random intercept models and network propagation.
HIV Infections
HIV-1-Tat Protein Inhibits SC35-mediated Tau Exon 10 Inclusion through Up-regulation of DYRK1A Kinase.
Hyperhomocysteinemia
Corrective effects of hepatotoxicity by hepatic Dyrk1a gene delivery in mice with intermediate hyperhomocysteinemia.
Hyperhomocysteinemia
DYRK1A, a novel determinant of the methionine-homocysteine cycle in different mouse models overexpressing this Down-syndrome-associated kinase.
Hyperhomocysteinemia
Dyrk1A, a Serine/Threonine Kinase, is Involved in ERK and Akt Activation in the Brain of Hyperhomocysteinemic Mice.
Hyperhomocysteinemia
Effect of hyperhomocysteinemia on the protein kinase DYRK1A in liver of mice.
Hyperhomocysteinemia
Hepatocyte-specific Dyrk1a gene transfer rescues plasma apolipoprotein A-I levels and aortic Akt/GSK3 pathways in hyperhomocysteinemic mice.
Hyperhomocysteinemia
Homocysteine-lowering gene therapy rescues signaling pathways in brain of mice with intermediate hyperhomocysteinemia.
Hyperhomocysteinemia
Hyperhomocysteinemia-induced Dyrk1a downregulation results in cardiomyocyte hypertrophy in rats.
Hyperhomocysteinemia
Mice Deficient in Cystathionine Beta Synthase Display Increased Dyrk1A and SAHH Activities in Brain.
Hypertension
Identification of different side effects between PARP inhibitors and their polypharmacological multi-target rationale.
Hypospadias
Microdeletion of the Down syndrome critical region at 21q22.
Hypothyroidism
Down syndrome and thyroid dysfunction: should nutritional support be the first-line treatment?
Infections
DYRK1 is a co-activator of FKHR (FOXO1a)-dependent glucose-6-phosphatase gene expression.
Infections
In vivo and in vitro phosphorylation of DNA-dependent RNA polymerase of Escherichia coli by bacteriophage-T7-induced protein kinase.
Infections
Protein kinase of bacteriophage T7. 1. Purification.
Infections
The serine/threonine/tyrosine kinase STY46 defends against hordeivirus infection by phosphorylating ?b protein.
Infections
Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.
Inflammatory Breast Neoplasms
A reciprocal tensin-3-cten switch mediates EGF-driven mammary cell migration.
Influenza, Human
Identification of Host Kinase Genes Required for Influenza Virus Replication and the Regulatory Role of MicroRNAs.
Insulin Resistance
Dual-specificity tyrosine phosphorylation-regulated kinase 1A ameliorates insulin resistance in neurons by up-regulating IRS-1 expression.
Intellectual Disability
A De Novo Mutation in DYRK1A Causes Syndromic Intellectual Disability: A Chinese Case Report.
Intellectual Disability
A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase.
Intellectual Disability
Abnormalities of DYRK1A-Cytoskeleton Complexes in the Blood Cells as Potential Biomarkers of Alzheimer's Disease.
Intellectual Disability
Activation, regulation, and inhibition of DYRK1A.
Intellectual Disability
Activity-Dependent Phosphorylation of Dynamin 1 at Serine 857.
Intellectual Disability
Alterations in the phenotype of neocortical pyramidal cells in the Dyrk1A+/- mouse.
Intellectual Disability
Case report of novel DYRK1A mutations in 2 individuals with syndromic intellectual disability and a review of the literature.
Intellectual Disability
Clinical manifestations of the deletion of Down syndrome critical region including DYRK1A and KCNJ6.
Intellectual Disability
Cloning and characterization of DYRK1B, a novel member of the DYRK family of protein kinases.
Intellectual Disability
Dyrk1 inhibition improves Alzheimer's disease-like pathology.
Intellectual Disability
DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects.
Intellectual Disability
DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.
Intellectual Disability
DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers.
Intellectual Disability
Dyrk1a Mutations Cause Undergrowth of Cortical Pyramidal Neurons via Dysregulated Growth Factor Signaling.
Intellectual Disability
DYRK1A pathogenic variants in two patients with syndromic intellectual disability and a review of the literature.
Intellectual Disability
Dyrk1A phosphorylates alpha-synuclein and enhances intracellular inclusion formation.
Intellectual Disability
Dyrk1A potentiates steroid hormone-induced transcription via the chromatin remodeling factor Arip4.
Intellectual Disability
DYRK1A, a Dosage-Sensitive Gene Involved in Neurodevelopmental Disorders, Is a Target for Drug Development in Down Syndrome.
Intellectual Disability
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
Intellectual Disability
Effect of DYRK1A activity inhibition on development of neuronal progenitors isolated from Ts65Dn mice.
Intellectual Disability
Functional characterization of DYRK1A missense variants associated with a syndromic form of intellectual deficiency and autism.
Intellectual Disability
Gene dosage-dependent association of DYRK1A with the cytoskeleton in the brain and lymphocytes of down syndrome patients.
Intellectual Disability
Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
Intellectual Disability
Integrative approach to interpret DYRK1A variants, leading to a frequent neurodevelopmental disorder.
Intellectual Disability
Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly.
Intellectual Disability
Negative-feedback inhibition of NFATc1 by DYRK1A regulates bone homeostasis.
Intellectual Disability
Neurodevelopmental delay, motor abnormalities and cognitive deficits in transgenic mice overexpressing Dyrk1A (minibrain), a murine model of Down's syndrome.
Intellectual Disability
Novel Causative Variants in DYRK1A, KARS, and KAT6A Associated with Intellectual Disability and Additional Phenotypic Features.
Intellectual Disability
Ocular findings of albinism in DYRK1A-related intellectual disability syndrome.
Intellectual Disability
Ocular Phenotype Associated with DYRK1A Variants.
Intellectual Disability
Overexpression of Dyrk1A Causes the Defects in Synaptic Vesicle Endocytosis.
Intellectual Disability
Overexpression of DYRK1A inhibits choline acetyltransferase induction by oleic acid in cellular models of Down syndrome.
Intellectual Disability
QSAR and Pharmacophore Study of Dyrk1A Inhibitory Meridianin Analogs as Potential Agents for Treatment of Neurodegenerative Diseases.
Intellectual Disability
Regulation of the proapoptotic activity of huntingtin interacting protein 1 by Dyrk1 and caspase-3 in hippocampal neuroprogenitor cells.
Intellectual Disability
Restoring microglial and astroglial homeostasis using DNA immunization in a Down Syndrome mouse model.
Intellectual Disability
Restrained Phosphatidylcholine Synthesis in a Cellular Model of Down's Syndrome is Associated with the Overexpression of Dyrk1A.
Intellectual Disability
Structural and functional characteristics of Dyrk, a novel subfamily of protein kinases with dual specificity.
Intellectual Disability
Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.
Intellectual Disability
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy.
Intellectual Disability
The neurodevelopmental disorder risk gene DYRK1A is required for ciliogenesis and control of brain size in Xenopus embryos.
Intellectual Disability
The role of DYRK1A in neurodegenerative diseases.
Intellectual Disability
Unraveling the genetic etiology of adult antisocial behavior: a genome-wide association study.
Intellectual Disability
[Identification of a de novo interstitial 21q22.12q22.13 deletion in a patient with intellectual disability].
Intellectual Disability
[Minibrain/DYRK1A gene: candidate gene for mental retardation in Down's syndrome?]
Kidney Failure, Chronic
Corrective effects of hepatotoxicity by hepatic Dyrk1a gene delivery in mice with intermediate hyperhomocysteinemia.
Language Development Disorders
Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
Learning Disabilities
Overexpression of Dyrk1A is implicated in several cognitive, electrophysiological and neuromorphological alterations found in a mouse model of Down syndrome.
Leukemia
DYRK1A phoshorylates histone H3 to differentially regulate the binding of HP1 isoforms and antagonize HP1-mediated transcriptional repression.
Leukemia
DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells.
Leukemia
Increased dosage of the chromosome 21 ortholog Dyrk1a promotes megakaryoblastic leukemia in a murine model of Down syndrome.
Leukemia
KLF4 Represses DYRK2 Inhibition of Self-renewal and Survival Through c-Myc and p53 in Leukemia Stem/Progenitor Cells.
Leukemia
Nuclear trafficking of pro-apoptotic kinases in response to DNA damage.
Leukemia
Overexpression of Serine Threonine Tyrosine Kinase 1/Novel Oncogene with Kinase Domain mRNA in Patients with Acute Leukemia.
Leukemia
The biology, pathogenesis and clinical aspects of acute lymphoblastic leukemia in children with Down syndrome.
Leukemia, Lymphoid
The murine PKR tumor suppressor gene is rearranged in a lymphocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
DYRK2 controls a key regulatory network in chronic myeloid leukemia stem cells.
Leukemia, Myeloid
Overexpression of chromatin remodeling and tyrosine kinase genes in iAMP21-positive acute lymphoblastic leukemia.
Lipoma
Identification of novel HMGA2 fusion sequences in lipoma: Evidence that deletion of let-7 miRNA consensus binding site 1 in the HMGA2 3' UTR is not critical for HMGA2 transcriptional upregulation.
Liposarcoma
Targeting DYRK1B suppresses the proliferation and migration of liposarcoma cells.
Liver Diseases
Corrective effects of hepatotoxicity by hepatic Dyrk1a gene delivery in mice with intermediate hyperhomocysteinemia.
Liver Neoplasms
Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
Liver Neoplasms
Utility of the dual-specificity protein kinase TTK as a therapeutic target for intrahepatic spread of liver cancer.
Lung Neoplasms
DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
Lung Neoplasms
DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.
Lung Neoplasms
DYRK2 expression may be a predictive marker for chemotherapy in non-small cell lung cancer.
Lung Neoplasms
Emerging roles of DYRK2 in cancer.
Lung Neoplasms
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Lung Neoplasms
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Lung Neoplasms
STYK1/NOK Promotes Metastasis and Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer by Suppressing FoxO1 Signaling.
Lymphatic Metastasis
[Expression and clinical significance of Dyrk1b in the specimens and cells of cervical lesions].
Lymphoma
Altered regulation of cyclic AMP-dependent protein kinase in a mouse lymphoma cell line.
Lymphoma
Subunit interaction in cyclic AMP-dependent protein kinase of mutant lymphoma cells.
Lymphoma, B-Cell
Hepato-protective effect of rutin via IL-6/STAT3 pathway in CCl4-induced hepatotoxicity in rats.
Lymphoma, Non-Hodgkin
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Memory Disorders
Cbs overdosage is necessary and sufficient to induce cognitive phenotypes in mouse models of Down syndrome and interacts genetically with Dyrk1a.
Memory Disorders
Correction of cognitive deficits in mouse models of Down syndrome by a pharmacological inhibitor of DYRK1A.
Memory Disorders
DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B.
Memory Disorders
Dual-specificity tyrosine phosphorylation-regulated kinase 1A does not require tyrosine phosphorylation for activity in vitro.
Memory Disorders
DYRK1A BAC transgenic mice show altered synaptic plasticity with learning and memory defects.
Memory Disorders
Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice.
Memory Disorders
Putative therapeutic agents for the learning and memory deficits of people with Down syndrome.
Memory Disorders
QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors.
Metabolic Syndrome
A form of the metabolic syndrome associated with mutations in DYRK1B.
Metabolic Syndrome
Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
Metabolic Syndrome
DYRK1B mutations associated with metabolic syndrome impair the chaperone-dependent maturation of the kinase domain.
Metabolic Syndrome
DYRK1B variant linked to autosomal dominant metabolic syndrome.
Metabolic Syndrome
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.
Metabolic Syndrome
Minibrain-related kinase/dual-specificity tyrosine-regulated kinase 1B implication in stem/cancer stem cells biology.
Metabolic Syndrome
Mutational analysis of two residues in the DYRK homology box of the protein kinase DYRK1A.
Metabolic Syndrome
Study of DYRK1B gene expression and its association with metabolic syndrome in a small cohort of Egyptians.
Metabolic Syndrome
The metabolic syndrome and DYRK1B.
Microcephaly
Case report of novel DYRK1A mutations in 2 individuals with syndromic intellectual disability and a review of the literature.
Microcephaly
DYRK1A haploinsufficiency causes a new recognizable syndrome with microcephaly, intellectual disability, speech impairment, and distinct facies.
Microcephaly
DYRK1A interacts with histone acetyl transferase p300 and CBP and localizes to enhancers.
Microcephaly
Dyrk1a Mutations Cause Undergrowth of Cortical Pyramidal Neurons via Dysregulated Growth Factor Signaling.
Microcephaly
DYRK1A mutations in two unrelated patients.
Microcephaly
DYRK1A pathogenic variants in two patients with syndromic intellectual disability and a review of the literature.
Microcephaly
DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease.
Microcephaly
DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures.
Microcephaly
DYRK1A: A master regulatory protein controlling brain growth.
Microcephaly
Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
Microcephaly
Generation of improved human cerebral organoids from single copy DYRK1A knockout induced pluripotent stem cells in trisomy 21: hypothetical solutions for neurodevelopmental models and therapeutic alternatives in down syndrome.
Microcephaly
Global kinome profiling reveals DYRK1A as critical activator of the human mitochondrial import machinery.
Microcephaly
Inhibition of DYRK1A disrupts neural lineage specification in human pluripotent stem cells.
Microcephaly
Intragenic deletion in DYRK1A leads to mental retardation and primary microcephaly.
Microcephaly
Investigation of copy number variations on chromosome 21 detected by comparative genomic hybridization (CGH) microarray in patients with congenital anomalies.
Microcephaly
Microdeletion of the Down syndrome critical region at 21q22.
Microcephaly
Novel Causative Variants in DYRK1A, KARS, and KAT6A Associated with Intellectual Disability and Additional Phenotypic Features.
Microcephaly
Precision Revisited: Targeting Microcephaly Kinases in Brain Tumors.
Microcephaly
Targeted next-generation sequencing in the diagnosis of neurodevelopmental disorders.
Microcephaly
Ten new cases further delineate the syndromic intellectual disability phenotype caused by mutations in DYRK1A.
Microcephaly
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy.
Microcephaly
The neurodevelopmental disorder risk gene DYRK1A is required for ciliogenesis and control of brain size in Xenopus embryos.
Microcephaly
Truncation of the Down syndrome candidate gene DYRK1A in two unrelated patients with microcephaly.
Neoplasm Metastasis
Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Neoplasm Metastasis
DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Neoplasm Metastasis
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
Neoplasm Metastasis
STYK1/NOK Promotes Metastasis and Epithelial-Mesenchymal Transition in Non-small Cell Lung Cancer by Suppressing FoxO1 Signaling.
Neoplasm Metastasis
[Expression and clinical significance of Dyrk1b in the specimens and cells of cervical lesions].
Neoplasms
A cell-based screening method for specifically detecting kinase activity.
Neoplasms
A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Neoplasms
A novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3? to phosphorylate cyclin D1 at Thr(286), not Thr(288).
Neoplasms
A wake-up call to quiescent cancer cells - potential use of DYRK1B inhibitors in cancer therapy.
Neoplasms
Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients.
Neoplasms
Ablation of miR-10b Suppresses Oncogene-Induced Mammary Tumorigenesis and Metastasis and Reactivates Tumor-Suppressive Pathways.
Neoplasms
Amplification and overexpression of the dual-specificity tyrosine-(Y)-phosphorylation regulated kinase 2 (DYRK2) gene in esophageal and lung adenocarcinomas.
Neoplasms
An ID2-dependent mechanism for VHL inactivation in cancer.
Neoplasms
Ancient drug curcumin impedes 26S proteasome activity by direct inhibition of dual-specificity tyrosine-regulated kinase 2.
Neoplasms
Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events.
Neoplasms
Characterization of protein tyrosine kinase activity in murine Leydig tumor cells.
Neoplasms
CIRBP Knockdown Attenuates Tumourigenesis and Improves the Chemosensitivity of Pancreatic Cancer via the Downregulation of DYRK1B.
Neoplasms
Comparison of Cancer Cell Survival Triggered by Microtubule Damage after Turning Dyrk1B Kinase On and Off.
Neoplasms
Crystal structure of the catalytic domain of the mitotic checkpoint kinase Mps1 in complex with SP600125.
Neoplasms
Curcumin as an Alternative Epigenetic Modulator: Mechanism of Action and Potential Effects.
Neoplasms
Data supporting a pilot high-throughput screen of a drug library for identification of DYRK1A inhibitors and high-content imaging analysis of identified harmine analogs.
Neoplasms
Decrease of miR-622 expression suppresses migration and invasion by targeting regulation of DYRK2 in colorectal cancer cells.
Neoplasms
Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
Neoplasms
Diagnostic relevance of overexpressed serine threonine tyrosine kinase/novel oncogene with kinase domain (STYK1/ NOK) mRNA in colorectal cancer.
Neoplasms
Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1.
Neoplasms
Downregulated DYRK2 expression is associated with poor prognosis and Oxaliplatin resistance in hepatocellular carcinoma.
Neoplasms
Downregulation of dual-specificity tyrosine-regulated kinase 2 promotes tumor cell proliferation and invasion by enhancing cyclin-dependent kinase 14 expression in breast cancer.
Neoplasms
Downregulation of DYRK2 can be a predictor of recurrence in early stage breast cancer.
Neoplasms
Downregulation of GLUT3 impairs STYK1/NOK-mediated metabolic reprogramming and proliferation in NIH-3T3 cells.
Neoplasms
Dual Specificity Kinase DYRK3 Promotes Aggressiveness of Glioblastoma by Altering Mitochondrial Morphology and Function.
Neoplasms
Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase 1a (DYRK1a) Kinase Inhibitors as Potential Therapeutics.
Neoplasms
Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) inhibitors: a survey of recent patent literature.
Neoplasms
Dual-specificity tyrosine-regulated kinase 2 is a suppressor and potential prognostic marker for liver metastasis of colorectal cancer.
Neoplasms
DYRK1A in Down syndrome: an oncogene or tumor suppressor?
Neoplasms
DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.
Neoplasms
DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild-type NSCLC cells to AZD9291.
Neoplasms
DYRK1A is required for maintenance of cancer stemness, contributing to tumorigenic potential in oral/oropharyngeal squamous cell carcinoma.
Neoplasms
DYRK1A kinase inhibitors with emphasis on cancer.
Neoplasms
DYRK1A modulates c-MET in pancreatic ductal adenocarcinoma to drive tumour growth.
Neoplasms
DYRK1A Negatively Regulates CDK5-SOX2 Pathway and Self-Renewal of Glioblastoma Stem Cells.
Neoplasms
Dyrk1A promotes the proliferation, migration and invasion of fibroblast-like synoviocytes in rheumatoid arthritis via down-regulating Spry2 and activating the ERK MAPK pathway.
Neoplasms
DYRK1A suppression restrains Mcl-1 expression and sensitizes NSCLC cells to Bcl-2 inhibitors.
Neoplasms
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
Neoplasms
DYRK1A: the double-edged kinase as a protagonist in cell growth and tumorigenesis.
Neoplasms
DYRK1B as therapeutic target in Hedgehog/GLI-dependent cancer cells with Smoothened inhibitor resistance.
Neoplasms
Dyrk1B overexpression is associated with breast cancer growth and a poor prognosis.
Neoplasms
DYRK2 controls the epithelial-mesenchymal transition in breast cancer by degrading Snail.
Neoplasms
DYRK2 priming phosphorylation of c-Jun and c-Myc modulates cell cycle progression in human cancer cells.
Neoplasms
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Neoplasms
Effect of protein kinase inhibitors on activity of mammalian small heat-shock protein (HSP25) kinase.
Neoplasms
Emerging roles of DYRK2 in cancer.
Neoplasms
Engagement of DYRK2 in proper control for cell division.
Neoplasms
Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition.
Neoplasms
Exploring the link between germline and somatic genetic alterations in breast carcinogenesis.
Neoplasms
Forced expression of DYRK2 exerts anti-tumor effects via apoptotic induction in liver cancer.
Neoplasms
Fragment-Derived Selective Inhibitors of Dual-Specificity Kinases DYRK1A and DYRK1B.
Neoplasms
Frequent DYRK2 gene amplification in micropapillary element of lung adenocarcinoma - an implication in progression in EGFR-mutated lung adenocarcinoma.
Neoplasms
Gene amplification in esophageal adenocarcinomas and Barrett's with high-grade dysplasia.
Neoplasms
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells.
Neoplasms
Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma.
Neoplasms
How to design potent and selective DYRK1B inhibitors? Molecular modeling study.
Neoplasms
Human biliverdin reductase suppresses Goodpasture antigen-binding protein (GPBP) kinase activity: the reductase regulates tumor necrosis factor-alpha-NF-kappaB-dependent GPBP expression.
Neoplasms
Identification of DYRK1B as a substrate of ERK1/2 and characterisation of the kinase activity of DYRK1B mutants from cancer and metabolic syndrome.
Neoplasms
Identification of harmine and ?-carboline analogs from a high-throughput screen of an approved drug collection; profiling as differential inhibitors of DYRK1A and monoamine oxidase A and for in vitro and in vivo anti-cancer studies.
Neoplasms
Impairment of DYRK2 augments stem-like traits by promoting KLF4 expression in breast cancer.
Neoplasms
Impairment of DYRK2 by DNMT1?mediated transcription augments carcinogenesis in human colorectal cancer.
Neoplasms
Inhibition of dual-specificity tyrosine phosphorylation-regulated kinase 2 perturbs 26S proteasome-addicted neoplastic progression.
Neoplasms
Inhibition of DYRK1A destabilizes EGFR and reduces EGFR-dependent glioblastoma growth.
Neoplasms
Inhibition of DYRK1A-EGFR axis by p53-MDM2 cascade mediates the induction of cellular senescence.
Neoplasms
Isoform selectivity of harmine-conjugated 1,2,3-triazoles against human monoamine oxidase.
Neoplasms
K63-linked ubiquitination of DYRK1A by TRAF2 alleviates Sprouty 2-mediated degradation of EGFR.
Neoplasms
Low Expression of DYRK2 (Dual Specificity Tyrosine Phosphorylation Regulated Kinase 2) Correlates with Poor Prognosis in Colorectal Cancer.
Neoplasms
Map2k4 functions as a tumor suppressor in lung adenocarcinoma and inhibits tumor cell invasion by decreasing peroxisome proliferator-activated receptor ?2 expression.
Neoplasms
Minibrain and Wings apart control organ growth and tissue patterning through down-regulation of Capicua.
Neoplasms
Minibrain-related kinase/dual-specificity tyrosine-regulated kinase 1B implication in stem/cancer stem cells biology.
Neoplasms
Molecular basis underlying resistance to Mps1/TTK inhibitors.
Neoplasms
Molecular targets for tumour progression in gastrointestinal stromal tumours.
Neoplasms
Multi-layered proteomic analyses decode compositional and functional effects of cancer mutations on kinase complexes.
Neoplasms
Multiple functions of DYRK2 in cancer and tissue development.
Neoplasms
New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Neoplasms
Novel trisubstituted harmine derivatives with original in vitro anticancer activity.
Neoplasms
Optimization and validation of a DYRK1A TR-FRET assay for high-throughput screening.
Neoplasms
Phosphorylation-dependent regulation of the NOTCH1 intracellular domain by dual-specificity tyrosine-regulated kinase 2.
Neoplasms
Proline Hydroxylation Primes Protein Kinases for Autophosphorylation and Activation.
Neoplasms
Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors.
Neoplasms
Regulating protein breakdown through proteasome phosphorylation.
Neoplasms
Regulation of Glioma Cells Migration by DYRK2.
Neoplasms
Role of dual specificity tyrosine-phosphorylation-regulated kinase 1B (Dyrk1B) in S-phase entry of HPV E7 expressing cells from quiescence.
Neoplasms
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Neoplasms
Site-specific proteasome phosphorylation controls cell proliferation and tumorigenesis.
Neoplasms
Small Molecule Inhibitors of DYRK1A Identified by Computational and Experimental Approaches.
Neoplasms
Structure-Guided Discovery of Potent and Selective DYRK1A Inhibitors.
Neoplasms
STYK1 promotes autophagy through enhancing the assembly of autophagy-specific class III phosphatidylinositol 3-kinase complex I.
Neoplasms
STYK1 promotes epithelial-mesenchymal transition and tumor metastasis in human hepatocellular carcinoma through MEK/ERK and PI3K/AKT signaling.
Neoplasms
Synthesis and biological activities of aminopyrimidyl-indoles structurally related to meridianins.
Neoplasms
Synthesis and in vitro evaluation of diverse heterocyclic diphenolic compounds as inhibitors of DYRK1A.
Neoplasms
Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition.
Neoplasms
The Human Novel Gene LNC-HC Inhibits Hepatocellular Carcinoma Cell Proliferation by Sequestering hsa-miR-183-5p.
Neoplasms
The nuclear interactome of DYRK1A reveals a functional role in DNA damage repair.
Neoplasms
The stress-responsive kinase DYRK2 activates heat shock factor 1 promoting resistance to proteotoxic stress.
Neoplasms
The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase.
Neoplasms
The USP22 promotes the growth of cancer cells through the DYRK1A in pancreatic ductal adenocarcinoma.
Neoplasms
TROAP switches DYRK1 activity to drive hepatocellular carcinoma progression.
Neoplasms
Tumor suppressor DYRK1A effects on proliferation and chemoresistance of AML cells by downregulating c-Myc.
Neoplasms
Tumour necrosis factor alpha enhances the expression of hydroxyl lyase, cytoplasmic antiproteinase-2 and a dual specificity kinase TTK in human chondrocyte-like cells.
Neoplasms
Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.
Neoplasms
Up-regulation of Dyrk1b promote astrocyte activation following lipopolysaccharide-induced neuroinflammation.
Neoplasms
Updating dual-specificity tyrosine-phosphorylation-regulated kinase 2 (DYRK2): molecular basis, functions and role in diseases.
Neoplasms
Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish.
Neoplasms
[Expression and clinical significance of Dyrk1b in the specimens and cells of cervical lesions].
Nervous System Diseases
Development of Kinase-Selective, Harmine-Based DYRK1A Inhibitors that Induce Pancreatic Human ?-Cell Proliferation.
Nervous System Diseases
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Nervous System Diseases
Novel selective thiadiazine DYRK1A inhibitor lead scaffold with human pancreatic ?-cell proliferation activity.
Neuroblastoma
DYRK3 contributes to differentiation and hypoxic control in neuroblastoma.
Neuroblastoma
Epigallocatechin-3-gallate inhibits the growth of three-dimensional in vitro models of neuroblastoma cell SH-SY5Y.
Neuroblastoma
Functional Interactions between BM88/Cend1, Ran-binding protein M and Dyrk1B kinase affect cyclin D1 levels and cell cycle progression/exit in mouse neuroblastoma cells.
Neuroblastoma
Harmine, a dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor induces caspase-mediated apoptosis in neuroblastoma.
Neuroblastoma
Iron-induced oxidative stress activates AKT and ERK1/2 and decreases Dyrk1B and PRMT1 in neuroblastoma SH-SY5Y cells.
Neuroblastoma
Participation of type II protein kinase A in the retinoic acid-induced growth inhibition of SH-SY5Y human neuroblastoma cells.
Neuroblastoma
Phosphorylation of endogenous proteins by adenosine 3':5'-monophosphate-dependent protein kinase in mouse neuroblastoma cells.
Neuroblastoma
Subcellular distribution of cyclin-dependent kinase-like 5 (CDKL5) is regulated through phosphorylation by dual specificity tyrosine-phosphorylation-regulated kinase 1A (DYRK1A).
Neuroblastoma
The Down syndrome-related protein kinase DYRK1A phosphorylates p27(Kip1) and Cyclin D1 and induces cell cycle exit and neuronal differentiation.
Neuroblastoma
The DYRK1A gene, encoded in chromosome 21 Down syndrome critical region, bridges between beta-amyloid production and tau phosphorylation in Alzheimer disease.
Neuroblastoma
Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish.
Neurodegenerative Diseases
A high-performance liquid chromatography assay for Dyrk1a, a Down syndrome-associated kinase.
Neurodegenerative Diseases
Activation, regulation, and inhibition of DYRK1A.
Neurodegenerative Diseases
Computational & experimental evaluation of the structure/activity relationship of ?-carbolines as DYRK1A inhibitors.
Neurodegenerative Diseases
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Neurodegenerative Diseases
Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors.
Neurodegenerative Diseases
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Neurodegenerative Diseases
DYRK1A and cognition: A lifelong relationship.
Neurodegenerative Diseases
DYRK1A inhibition as potential treatment for Alzheimer's disease.
Neurodegenerative Diseases
DYRK1A: a down syndrome-related dual protein kinase with a versatile role in tumorigenesis.
Neurodegenerative Diseases
Further investigation of Paprotrain: Towards the conception of selective and multi-targeted CNS kinase inhibitors.
Neurodegenerative Diseases
Homocysteine-lowering gene therapy rescues signaling pathways in brain of mice with intermediate hyperhomocysteinemia.
Neurodegenerative Diseases
Library-based discovery of DYRK1A/CLK1 inhibitors from natural product extracts.
Neurodegenerative Diseases
Molecular Rescue of DYRK1A Overexpression in Cystathionine Beta Synthase-Deficient Mouse Brain by Enriched Environment Combined with Voluntary Exercise.
Neurodegenerative Diseases
New pyrido[3,4-g]quinazoline derivatives as CLK1 and DYRK1A inhibitors: synthesis, biological evaluation and binding mode analysis.
Neurodegenerative Diseases
Oxidative and nitrosative modifications of biliverdin reductase-a in the brain of subjects with Alzheimer's disease and amnestic mild cognitive impairment.
Neurodegenerative Diseases
QSAR and Pharmacophore Study of Dyrk1A Inhibitory Meridianin Analogs as Potential Agents for Treatment of Neurodegenerative Diseases.
Neurodegenerative Diseases
Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?
Neurodegenerative Diseases
Selective DYRK1A Inhibitor for the Treatment of Neurodegenerative Diseases: Alzheimer, Parkinson, Huntington, and Down Syndrome.
Neurodegenerative Diseases
Selectivity Profiling and Biological Activity of Novel ?-Carbolines as Potent and Selective DYRK1 Kinase Inhibitors.
Neurodegenerative Diseases
Synthesis, Resolution, and Biological Evaluation of Atropisomeric (aR)- and (aS)-16-Methyllamellarins N: Unique Effects of the Axial Chirality on the Selectivity of Protein Kinases Inhibition.
Neurodegenerative Diseases
The Down syndrome candidate dual-specificity tyrosine phosphorylation-regulated kinase 1A phosphorylates the neurodegeneration-related septin 4.
Neurodegenerative Diseases
The role of DYRK1A in neurodegenerative diseases.
Neurodegenerative Diseases
[b]-Annulated Halogen-Substituted Indoles as Potential DYRK1A Inhibitors.
Neuroinflammatory Diseases
Dyrk2 involved in regulating LPS-induced neuronal apoptosis.
Neuroinflammatory Diseases
Dyrk2 mediated the release of proinflammatory cytokines in LPS-induced BV2 cells.
Neuroinflammatory Diseases
Tau pathology reduction with SM07883, a novel, potent, and selective oral DYRK1A inhibitor: A potential therapeutic for Alzheimer's disease.
Neuroinflammatory Diseases
The novel DYRK1A inhibitor KVN93 regulates cognitive function, amyloid-beta pathology, and neuroinflammation.
Neuroinflammatory Diseases
Up-regulation of Dyrk1b promote astrocyte activation following lipopolysaccharide-induced neuroinflammation.
Obesity
Design and synthesis of a potent inhibitor of class 1 DYRK kinases as a suppressor of adipogenesis.
Obesity
Phosphorylation and Inactivation of Glycogen Synthase Kinase 3? (GSK3?) by Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A).
Oligodendroglioma
Minibrain and Wings apart control organ growth and tissue patterning through down-regulation of Capicua.
Optic Atrophy
High diagnostic yield of clinically unidentifiable syndromic growth disorders by targeted exome sequencing.
Optic Nerve Hypoplasia
Ocular Phenotype Associated with DYRK1A Variants.
Osteoarthritis, Knee
Lorecivivint, a Novel Intraarticular CDC-Like Kinase 2 and Dual-Specificity Tyrosine Phosphorylation-Regulated Kinase 1A Inhibitor and Wnt Pathway Modulator for the Treatment of Knee Osteoarthritis: A Phase II Randomized Trial.
Osteoarthritis, Knee
Modulation of the Wnt pathway through inhibition of CLK2 and DYRK1A by lorecivivint as a novel, potentially disease-modifying approach for knee osteoarthritis treatment.
Ovarian Neoplasms
DYRK1B blocks canonical and promotes non-canonical Hedgehog signaling through activation of the mTOR/AKT pathway.
Ovarian Neoplasms
DYRK2 regulates epithelial-mesenchymal-transition and chemosensitivity through Snail degradation in ovarian serous adenocarcinoma.
Pancreatic Neoplasms
CIRBP Knockdown Attenuates Tumourigenesis and Improves the Chemosensitivity of Pancreatic Cancer via the Downregulation of DYRK1B.
Pancreatic Neoplasms
Key role of dual specificity kinase TTK in proliferation and survival of pancreatic cancer cells.
Pancreatic Neoplasms
Licocoumarone induces BxPC-3 pancreatic adenocarcinoma cell death by inhibiting DYRK1A.
Parkinson Disease
A Pilot Study Examining Associations between DYRK1A and ?-Synuclein Dementias.
Parkinson Disease
Association of DYRK1A polymorphisms with sporadic Parkinson's disease in Chinese Han population.
Parkinson Disease
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Parkinson Disease
DYRK1A promotes dopaminergic neuron survival in the developing brain and in a mouse model of Parkinson's disease.
Parkinson Disease
GSK-3?, FYN, and DYRK1A: Master Regulators in Neurodegenerative Pathways.
Parkinson Disease
Understanding the Multifaceted Role of Human Down Syndrome Kinase DYRK1A.
Pick Disease of the Brain
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Pick Disease of the Brain
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Pituitary Neoplasms
Identification of Seven Cell Cycle-Related Genes with Unfavorable Prognosis and Construction of their TF-miRNA-mRNA regulatory network in Breast Cancer.
Plasmacytoma
Resolution and general properties of different types of ribosomal protein kinases in mouse plasmocytoma.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Doubling up on function: dual-specificity tyrosine-regulated kinase 1A (DYRK1A) in B cell acute lymphoblastic leukemia.
Precursor Cell Lymphoblastic Leukemia-Lymphoma
DYRK1A regulates B cell acute lymphoblastic leukemia through phosphorylation of FOXO1 and STAT3.
Prostatic Neoplasms
The Tumor Suppressor NKX3.1 Is Targeted for Degradation by DYRK1B Kinase.
Pseudolymphoma
Silencing of DYRK2 increases cell proliferation but reverses CAM-DR in Non-Hodgkin's Lymphoma.
Psoriasis
MicroRNA-215-5p inhibits the proliferation of keratinocytes and alleviates psoriasis-like inflammation by negatively regulating DYRK1A and its downstream signalling pathways.
Refractive Errors
Ocular Phenotype Associated with DYRK1A Variants.
Refsum Disease
Dual-specificity tyrosine-phosphorylated and regulated kinase 1A (DYRK1A) interacts with the phytanoyl-CoA alpha-hydroxylase associated protein 1 (PAHX-AP1), a brain specific protein.
Retinoblastoma
Global phosphoproteomics reveals DYRK1A regulates CDK1 activity in glioblastoma cells.
Rett Syndrome
Intellectual disabilities, neuronal posttranscriptional RNA metabolism, and RNA-binding proteins: three actors for a complex scenario.
Sarcoma
Viral src gene products are related to the catalytic chain of mammalian cAMP-dependent protein kinase.
Sarcoma, Avian
Cytosolic malic dehydrogenase activity is associated with a putative substrate for the transforming gene product of Rous sarcoma virus.
Sarcoma, Avian
Protein kinase and its regulatory effect on reverse transcriptase activity of Rous sarcoma virus.
Scoliosis
Investigation of copy number variations on chromosome 21 detected by comparative genomic hybridization (CGH) microarray in patients with congenital anomalies.
Seizures
DYRK1A mutations in two unrelated patients.
Seizures
Excitation/inhibition balance and learning are modified by Dyrk1a gene dosage.
Seizures
Generation of an induced pluripotent stem cell line from a patient with global development delay carrying DYRK1A mutation (c.1730T>A) and a gene correction isogenic iPSC line.
Seizures
The DYRK1A gene is a cause of syndromic intellectual disability with severe microcephaly and epilepsy.
Seizures, Febrile
DYRK1A-haploinsufficiency in mice causes autistic-like features and febrile seizures.
Sepsis
Constructing a 10-core genes panel for diagnosis of pediatric sepsis.
Severe Acute Respiratory Syndrome
Host factor prioritization for pan-viral genetic perturbation screens using random intercept models and network propagation.
Squamous Cell Carcinoma of Head and Neck
A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Squamous Cell Carcinoma of Head and Neck
Corrigendum: A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Status Epilepticus
miRNA-187-3p-mediated regulation of the KCNK10/TREK-2 potassium channel in a rat epilepsy model.
Strabismus
Ocular Phenotype Associated with DYRK1A Variants.
Stroke
Genome-wide meta-analysis identifies 3 novel loci associated with stroke.
Stroke
LIM kinase inhibitor T56-LIMKi protects mouse brain from photothrombotic stroke.
Tauopathies
Constitutive Dyrk1A is abnormally expressed in Alzheimer disease, Down syndrome, Pick disease, and related transgenic models.
Tauopathies
Dual-specificity Tyrosine Phosphorylation-regulated Kinase 1A (Dyrk1A) Enhances Tau Expression.
Tauopathies
Dual-Specificity, Tyrosine Phosphorylation-Regulated Kinases (DYRKs) and cdc2-Like Kinases (CLKs) in Human Disease, an Overview.
Thyroid Dysgenesis
DYRK1A BAC Transgenic Mouse: A New Model of Thyroid Dysgenesis in Down Syndrome.
Triple Negative Breast Neoplasms
Emerging roles of DYRK2 in cancer.
Urinary Bladder Neoplasms
Dual-specificity tyrosine phosphorylation-regulated kinase 2 (DYRK2) as a novel marker in T1 high-grade and T2 bladder cancer patients receiving neoadjuvant chemotherapy.
Uterine Cervical Neoplasms
[Expression and clinical significance of Dyrk1b in the specimens and cells of cervical lesions].
Uterine Cervicitis
[Expression and clinical significance of Dyrk1b in the specimens and cells of cervical lesions].
Vascular Diseases
Vascular defects of DYRK1A knockouts are ameliorated by modulating calcium signaling in zebrafish.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
2.7.12.1 dual-specificity kinase
more
top
The reliability class of the localization prediction ranges from 1 (very reliable) to 5 (not reliable). 
